Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

12

Revenue 2017

Bayer

The Top Pharma List rankings are compiled from GlobalData's pharmaceutical revenue figures, which are based on prescription medicine sales, including generics drugs. They have been compiled below into an infographic of Bayer's 2013 sales performance.

Bayer

Aveo’s tivozanib is knocked back by FDA once again

Aveo’s tivozanib is knocked back by FDA once again the TIVO-1 trial of VEGF inhibitor tivozanib – then partnered with Astellas – which compared the drug to Bayer’s VEGF drug Nexavar (sorafenib) in renal cell carcinoma (RCC).

New faces at Healthware Group and HRW

New faces at Healthware Group and HRW Commenting on her new role, Milburn said “from CVS and Sleepio to OneDrop and Bayer, to Happify and Sanofi, every day more and more strategic partnerships are being born between various

Roche eyes filings for Tecentriq/Avastin combo in liver cancer

Roche eyes filings for Tecentriq/Avastin combo in liver cancer plus anti-VEGF antibody Avastin (bevacizumab) or Bayer’s Nexavar (sorafenib), a standard first-line therapy for HCC.

Finalists

by AbbVie. with support from Lucid Group. Marketing Capability Development. by Bayer Russia.

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD

Novartis bags US okay for Lucentis follow-up Beovu in wet AMD Novartis’ drug was the first VEGF inhibitor to reach the market for wet AMD but is facing the triple challenge of Bayer/Regeneron’s rival drug  Eylea (aflibercept) – now the market ... and Bayer adding another $2.1bn from other markets.

[ Previous 5 results ] 4 5 6 7 8 9 10 11 12 13 [ Next 5 results ]

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Porterhouse Medical Group

The Porterhouse Medical Group provides powerful, insight-driven, scientific and medical communication services to the pharmaceutical industry across the globe, with...

Latest intelligence

Working together against COVID-19
Analysing social media conversations to see what HCPs are saying online about the global pandemic...
Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
Are biobetters a market access opportunity?
Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....

Infographics